Sugi Predict

Sugi Predict / Compounds / SCHEMBL29387178

SCHEMBL29387178

SCHEMBL29387178

CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)N4CCC[C@H]4C(=O)N[C@@H](Cc4c[nH]cn4)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC1=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N3)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC2=O)C(C)C)[C@@H](C)CC

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ INSR P06213 1/20 0.59
▸ NPY2R P49146 6/20 0.56
▸ RAMP1 O60894 1/20 0.56
▸ RAMP2 O60895 1/20 0.56
▸ RAMP3 O60896 1/20 0.56
▸ CALCR P30988 1/20 0.56
▸ CALCRL Q16602 1/20 0.56
▸ MC4R P32245 2/20 0.56
▸ MC1R Q01726 2/20 0.56
▸ MC3R P41968 1/20 0.55
▸ KCNMA1 Q12791 1/20 0.54
▸ KCNMB4 Q86W47 1/20 0.54
▸ PRLHR P49683 5/20 0.53
▸ KCNA3 P22001 1/20 0.53
▸ KCNA1 Q09470 1/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.51
▸ KLK5 Q9Y337 1/20 0.51
▸ NPR1 P16066 1/20 0.51
▸ NPR3 P17342 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390185 0.90 MC4R (0.63) INSRNPY2RMC4RMC1RMC3R
SCHEMBL29904330 0.88 INSR (0.58) INSRNPY2RRAMP1RAMP2RAMP3
SCHEMBL29965049 0.88 INSR (0.62) INSRNPY2RRAMP1RAMP2RAMP3
SCHEMBL31736960 0.87 INSR (0.59) INSRNPY2RRAMP1RAMP2RAMP3
SCHEMBL29511745 0.86 INSR (0.61) INSRNPY2RRAMP1RAMP2RAMP3
SCHEMBL29387159 0.85 INSR (0.60) INSRNPY2RRAMP1RAMP2RAMP3
SCHEMBL29964088 0.85 INSR (0.56) INSRNPY2RRAMP1RAMP2RAMP3
SCHEMBL29389145 0.81 MC4R (0.65) INSRNPY2RMC4RMC1RMC3R
SCHEMBL29387182 0.79 KCNMA1 (0.62) INSRMC4RMC1RMC3RKCNMA1
SCHEMBL29356113 0.77 TEAD4 (0.62) MC4RMC1RMC3RKCNA3KCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-221595643-U High-speed serial port conversion module based on FPGA 天津云遥宇航科技有限公司 2024-08-23 — — CN claimed
CN-111078626-B High-speed communication sub-mother board for big data transmission and use method thereof 北京航天福道高技术股份有限公司 2024-05-10 — — CN claimed
CN-112422165-B Airborne information safety module based on software radio 中国电子信息产业集团有限公司第六研究所 2022-06-21 — — CN claimed
US-20260115332-A1 Fibroblast Activation Protein Alpha-Cleavable Pro-Peptides and Methods of Use UNIV CALIFORNIA (US) 2026-04-30 — — US disclosed
US-20260116983-A1 Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use UNIV CALIFORNIA (US) 2026-04-30 — — US disclosed
US-12606937-B2 Humanized antibodies with ultralong complementary determining regions TAURUS BIOSCIENCES, LLC (US) 2026-04-21 — — US disclosed
US-20260102377-A1 COMPOSITIONS AND METHODS FOR TREATING MYASTHENIA GRAVIS NMD PHARMA A/S (DK) 2026-04-16 — — US disclosed
US-20260086099-A1 BIOMARKER FOR MYASTHENIA GRAVIS HEINRICH HEINE UNIV DUESSELDORF (DE) 2026-03-26 — — US disclosed
US-12545668-B2 Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof TORAY INDUSTRIES, INC. (JP) 2026-02-10 — — US disclosed
US-20260031935-A1 PACKET DATA CONVERGENCE PROTOCOL RETRANSMISSION FOR CELL-FREE CONNECTIVITY APPLE INC (US) 2026-01-29 — — US disclosed
WO-2025241040-A1 PEPTIDES DERIVED FROM THE VENOM OF THE HETEROCTENUS JUNCEUS SCORPION, ITS VARIANTS, COMPOSITIONS, METHODS AND USES BLUE SCORPION GROUP INC (US) 2025-11-27 — — WO disclosed
CN-108093640-B Site-specific antibody-drug conjugates ADC治疗股份有限公司 2022-05-17 — — CN disclosed
US-20220145175-A1 Near-Infrared-II Nanoparticles and Related Compositions and Methods THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-05-12 — — US disclosed
US-11292820-B2 KV1.3 blockers ZEALAND PHARMA A/S (DK) 2022-04-05 — — US disclosed
EP-3972647-A1 DRUG CONJUGATES AND METHODS OF USING SAME The Board Of Trustees Of The Leland Stanford Junior University (US) 2022-03-30 — — EP disclosed
US-11278595-B2 Peptides comprising non-natural amino acids and methods of making and using the same LONGEVITY BIOTECH, INC. (US) 2022-03-22 — — US disclosed
US-20220081431-A1 CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2022-03-17 — — US disclosed
EP-3157955-B1 KV1.3 BINDING IMMUNOGLOBULINS ABLYNX NV (BE) 2022-03-16 — — EP disclosed
US-11274158-B2 Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-03-15 — — US disclosed
US-20220054499-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2022-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606937-B2 Humanized antibodies with ultralong complementary determining regions IGLV6-57, FCGR3B, VSIR INSR 1021/4885NPY2R 340/4885RAMP1 2866/4885
US-12545668-B2 Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof SSB, TLR9, C5AR2 INSR 4828/4885NPY2R 3939/4885RAMP1 1995/4885
US-20220054499-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 INSR 3492/4885NPY2R 4339/4885RAMP1 3379/4885
US-20260031935-A1 PACKET DATA CONVERGENCE PROTOCOL RETRANSMISSION FOR CELL-FREE CONNECTIVITY TXNL1, TRRAP, HNRNPU INSR 766/4885NPY2R 708/4885RAMP1 903/4885
US-11278595-B2 Peptides comprising non-natural amino acids and methods of making and using the same APLNR, SCTR, GIPR INSR 23/4885NPY2R 183/4885RAMP1 423/4885
US-20260102377-A1 COMPOSITIONS AND METHODS FOR TREATING MYASTHENIA GRAVIS CHRNG, MUSK, PYGM INSR 3818/4885NPY2R 1127/4885RAMP1 1948/4885
US-20260116983-A1 Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use VSIG8, PLAUR, IGSF11 INSR 628/4885NPY2R 1580/4885RAMP1 934/4885
US-11292820-B2 KV1.3 blockers KCNA3, KCNK3, KCNN3 INSR 2284/4885NPY2R 1696/4885RAMP1 2686/4885
US-20260115332-A1 Fibroblast Activation Protein Alpha-Cleavable Pro-Peptides and Methods of Use FAP, FIBP, CTSL INSR 2281/4885NPY2R 2470/4885RAMP1 121/4885
US-20260086099-A1 BIOMARKER FOR MYASTHENIA GRAVIS HRH3, CHRNE, BCHE INSR 1907/4885NPY2R 4262/4885RAMP1 1039/4885
US-20220081431-A1 CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF ADCY10, ADCK5, AANAT INSR 4225/4885NPY2R 3433/4885RAMP1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.